Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 54–55

HOS-112192 · Präparat HOS-093615

54 Medicinal products by Interaction Recommendations therapeutic area concerning co-administration Ivosidenib The mechanism of interaction is CYP3A4 Co-administration of inhibition by atazanavir and/or ritonavir. ivosidenib with REYATAZ (with or without ritonavir) is contraindicated due to potential for loss of virologic response, development of resistance, increase in ivosidenib plasma concentration and subsequent risk of serious adverse events such as QT interval prolongation (see section 4.3). Irinotecan Atazanavir inhibits UGT and may interfere If REYATAZ is co- with the metabolism of irinotecan, resulting administered with irinotecan, in increased irinotecan toxicities. patients should be closely monitored for adverse events related to irinotecan. Immunosuppressants Cyclosporin Concentrations of these More frequent therapeutic Tacrolimus immunosuppressants may be increased concentration monitoring of Sirolimus when co-administered with REYATAZ due these medicinal products is to CYP3A4 inhibition. recommended until plasma levels have been stabilised. CARDIOVASCULAR AGENTS Antiarrhythmics Amiodarone, Concentrations of these antiarrhythmics Caution is warranted and Systemic lidocaine, may be increased when co-administered therapeutic concentration Quinidine with REYATAZ. The mechanism of monitoring is recommended amiodarone or systemic when available. The lidocaine/atazanavir interaction is CYP3A concomitant use of quinidine is inhibition. Quinidine has a narrow contraindicated (see therapeutic window and is contraindicated section 4.3). due to potential inhibition of CYP3A by REYATAZ. Calcium channel blockers Bepridil REYATAZ should not be used in Co-administration with combination with medicinal products that bepridil is contraindicated (see are substrates of CYP3A4 and have a section 4.3) narrow therapeutic index. Diltiazem 180 mg once daily Diltiazem AUC: ↑125% (↑109% ↑141%) An initial dose reduction of (atazanavir 400 mg once daily) Diltiazem Cmax: ↑98% (↑78% ↑119%) diltiazem by 50% is Diltiazem Cmin: ↑142% (↑114% ↑173%) recommended, with subsequent titration as needed and ECG Desacetyl-diltiazem AUC: ↑165% (↑145% monitoring. ↑187%) Desacetyl-diltiazem Cmax: ↑172% (↑144% ↑203%) Desacetyl-diltiazem Cmin: ↑121% (↑102% ↑142%)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) lidocaine (HOS-108866) bepridil (HOS-085612) quinidine (HOS-085593) calcium (HOS-085615) tacrolimus (HOS-085202) ivosidenib (HOS-112046) sirolimus (HOS-085172) ritonavir (HOS-084521) amiodarone (HOS-085596) irinotecan (HOS-112102)